Teva Pharmaceutical Industries Limited (NYSE:TEVA) dropped -0.31% and closed the trade at $ 51.74. The company recorded a trading capacity of 4.65 million shares below its three months average daily volume of 5.93 million shares. During the last trade, shares reached to high price of $52.01 and touched the low price of $51.45. The stock’s 50-day moving average is noted at $52.67 and its 200-day moving average is stands at $53.45.
Additionally, the company has a PE ratio of 34.56 and has EPS of 1.50. The company has market capitalization of $47.29B.
Currently Teva Pharmaceutical Industries Limited (TEVA) captured an average recommendation of “ Buy ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “21″ Analysts”. “0” rated “Sell” for the company. “6” said the company as a “Hold”. Overweight rating was given by “1” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $67.62 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $100.00 however minimum price target advised by analysts is $57.00. The Median price target for the stock is measured at $65.50.
Presently, Analysts decided consensus EPS estimate of $1.36 for present quarter and one month ago projected EPS estimate was at $1.36. If we take a look at back 3 month ago, consensus EPS estimate was $1.40.
A current consensus EPS estimate for next quarter is at $1.46 and 3 month ago EPS forecast was $1.45. Have a look at back 1 month ago, consensus EPS forecast was seen at $1.46.
For current fiscal year, most recent EPS estimate is set at $5.27 based on Analyst consensus and three month ago consensus EPS opinions was at $5.26. During period one month ago, consensus EPS forecast was decided at $5.28.
A current consensus EPS projection for next fiscal year is observed at $6.00 and one month ago consensus EPS forecast was at $6.02. Take a look at back three month ago, consensus EPS estimate opinions was decided at $5.95 by analysts.
One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 20 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 1. 7 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Buy derived from brokerage firms, according to FactSet. 20 said a “Buy Rating” and 1 announced “Overweight Rating”. 6 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.